CUE Share Price Performance
US$28.26
7.25 (34.53%)
59.6% undervalued intrinsic discount
US$70.00
Fair Value
Price US$28.26
Lou_Basenese US$70.00
Fair ValueUS$70.00
Share Pricen/a
Cue Biopharma, Inc. Stock Price
- 1 Narratives written by author
- 0 Comments on narratives written by author
- 54 Fair Values set on narratives written by author
CUE Community Narratives
LO
Fair Value
·Fair Value US$70 59.6% undervalued intrinsic discount
Cue Biopharma (NASDAQ: CUE): The Scientist Behind Xolair Just Gave Cue a Next-Generation Shot at the Same Multi-Billion-Dollar Market
10users have liked this narrative
0users have commented on this narrative
47users have followed this narrative
Cue Biopharma (NASDAQ: CUE): The Scientist Behind Xolair Just Gave Cue a Next-Generation Shot at the Same Multi-Billion-Dollar Market
Cue Biopharma bets its future on a new allergy drug designed by the same scientist who created Xolair, aiming to make treatment far less frequent for people with chronic hives and other allergic conditions. A key mid-stage trial result is coming soon, and it could either put Cue on big pharma’s radar or expose just how risky this turnaround really is.Read more
LO
US$70
59.6% undervalued intrinsic discount
Fair Value
Profit Margin
18.64%
Future PE
26.25x
Price in 2031
US$79.7
Trending Discussion
Recently Updated Narratives
No recently updated narratives available.
Snowflake Analysis
Cue Biopharma, Inc. Key Details
About CUE
- Founded
- 2014
- Employees
- 29
- CEO
- WebsiteView website
Cue Biopharma, Inc., a clinical-stage therapeutics company, focuses on developing various therapies for immunological disorders. The company’s lead asset is CUE-221, an anti-IgE antibody with a dual-mechanism of action currently in Phase 2 development for allergic diseases. It also developed the Immuno-STAT platform, which targets disease-specific T cells in vivo without broad immune modulation. The company’s lead autoimmune candidate is CUE-401, a bifunctional IL-2 and TGF-B program that is advancing towards Phase 1 development to regulate inflammation and drive Treg-mediated tolerance. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.
